

E. coli O103/Sushi (suspect)/Sep 2023 Executive Incident Summary CARA # 1192 Date: 1/8/2024

Authors:

CORE Signals & Surveillance Team: Tiffany Greenlee, MPH

CORE Response Team 1: Brooke M. Whitney, PhD

EXECUTIVE SUMMARY

Notification

On 9/27/2023, CORE Signals was notified by CDC about an *E. coli* O103 cluster (2309OHEXW-1) with a signal for sushi with 7 cases in 3 states: OH (4), SC (2), and TN (1). At the time of notification, 5 cases reported sushi and a subcluster of 3 cases in OH reported consuming food from the same sushi restaurant. Early in the investigation, avocados were pursued as an item of interest with record collection conducted at various points-of-service (POS) reported by cases; however, a common type or brand of avocado was not identified, and avocados were determined to be an unlikely vehicle. Restaurant invoices showed a potential common item received by some POS including whole salmon in sushi reported by cases, which emerged as an item of interest.

Epidemiology Overview & WGS

As of 12/5/2023, the CDC closeout date, this investigation included 12 cases across 5 states: FL (1), MO (1), OH (5), SC (3), and TN (2). All isolates were related within 0-3 alleles by cgMLST. Isolation dates ranged from 8/24/2023 to 10/12/2023 and reported onset dates (n=10) ranged from 8/19/2023 to 10/8/2023. Ages ranged from 1 year to 62 years old with a median of 28 years, and 5/12 (42%) cases were female. Outcome information was available for 11 cases, of which 7 had been hospitalized, and there were no reported deaths. There were no historical outbreaks related to this cluster. The NCBI tree was small and contained no nonclinical isolates.

Epi information at the time of closing was available for 10 cases. Notably, 9/10 (90%) of cases reported exposure to sushi at numerous sushi restaurants. All 9 sushi-consumers reported consuming a variety of different rolls, ranging from vegan rolls to raw fish rolls. The one case who did not report consuming sushi did report consuming a raw fish poke bowl purchased from (b)(4). Commonly reported ingredients included: salmon (5/10), tuna (4/10), crab (4/10), sushi rice (10/10), seaweed wrap/nori (8/10), avocado (8/10), and cucumber (6/10).

Field Investigations & Findings

No FDA inspections were requested. CORE issued five investigation assignments related to traceback information collection to various divisions within the FDA Office of Regulatory Affairs Human and Animal Foods. The firms for the assignments included: (b)(4)

Laboratory Sample Overview

No samples were collected as a result of this investigation.

Traceback Abbreviated Summary

Traceback was conducted on whole salmon for this incident as suggested based on the initial information prepared by investigational partners. Restaurant invoices for fresh produce and fish were requested from all reported sushi restaurants, and records were received from restaurants. Limited convergence was found in the traceback analysis for whole salmon. (b)(4) of the points-of-service (POS) received whole salmon from (b)(4)

[b)(4)

[b)(4)

[c)(b)(4)

[c)(b)(4)

other POS did not receive salmon from (b)(4)

. During the traceback investigation, tempura batter mix was identified as another common product received by restaurants in OH and TN. 4/11 cases reported a tempura-fried product, ranging from fried rolls to fried ingredients in sushi rolls, notably all three cases in an OH subcluster which received tempura batter mix from this supplier. Further traceback, however, was not practical given the lack of comprehensive invoices from other restaurants and inability to collect more epidemiologic information given the extended lag since the last case upload.

Product & Firm Actions

No product or firm actions were identified and taken for this incident.

Communications Overview

This incident was added to the CORE investigation table on 11/15/2023. It was closed on the CIT with no vehicle identified.

Conclusions

With the lack of laboratory, traceback, and inspectional evidence, the broad category of sushi remained the suspect vehicle for this outbreak investigation based on epidemiologic evidence alone. Shiga toxin-producing *E. coli* (STEC), such as *E. coli* O103, associated with sushi is an unusual pathogen-commodity pair and the specific contaminating ingredient(s) remain unknown. Questions posed to cases regarding sushi did not ask about tempura or tempura batter exposure, as the questions were focused on sushi. During this outbreak investigation, tempura batter mix was identified as a potential vehicle relatively late and the opportunity to re-interview and/or recollect appropriate invoices from restaurants were not feasible to thoroughly explore the potential for this vehicle. In future outbreaks with this pathogen-commodity pair, CDC will likely request additional information regarding tempura exposure.

INCIDENT COORDINATION GROUP

Office of Regulatory Affairs				
Human and Animal Food				
HAF East 1 (New	Kim Langello	Kimberly.Langello@fda.hhs.gov		
England)				
HAF East 3 (Atlanta)	Wilbur Huggins	Wilbur.Huggins@fda.hhs.gov		
	Tyrico English	Tyrico.English@fda.hhs.gov		
HAF East 4 (Florida)	Nelson Venerio	Nelson.Venerio@fda.hhs.gov		
HAF East 5 (Cincinnati)	Holly Smith (Acting	Holly.Smith@fda.hhs.gov		
	ERC)			
HAF East 5 (New	Lindsay Bertling	Lindsay.Bertling@fda.hhs.gov		
Orleans)				
HAF West 2 (Kansas	Erin Dugan	Erin.Dugan@fda.hhs.gov		
City)				
HAF West 3 (Dallas)	Travis Hunt	Travis.Hunt@fda.hhs.gov		
ORA Headquarters				

Domestic Human and	Linda Stewart	Linda.Stewart@fda.hhs.gov		
Animal Foods – Program	Monali Yajnik	Monali.Yajnik@fda.hhs.gov		
Operations Branch	Trionan Tajina	orahafoutbreakresponse@fda.hhs.gov		
Office of Human and	Lori Holmquist	Lori.Holmquist@fda.hhs.gov		
Animal Food Operations	Lon noniquist	Dom. Homelasto Journals. go v		
(OHAFO)				
Office of Human and	Kimberly Livsey	Kimberly.Livsey@fda.hhs.gov		
Animal Food Operations –	Holly Miller	Holly.Miller@fda.hhs.gov		
Senior ERC	Nicole Vaught	Nicole.Vaught@fda.hhs.gov		
Semor Exc	Tyleore vaught	orahafseniorercs@fda.hhs.gov		
Office of Regulatory	Evelyn Ladines	Evelyn.Ladines@fda.hhs.gov		
Science	L veryn Ladines	Lveryn.Ladines@ida.ims.gov		
Science				
Office of Policy,	Scott Loughan	Scott.Loughan@fda.hhs.gov		
Compliance &	Lisa Gilliam	Lisa.Gilliam@fda.hhs.gov		
Enforcement (Division of		orarecalloe@fda.hhs.gov		
Compliance &		eria conizco (@zumizzasigo :		
Enforcement, DCE)				
	Office of the Con	nmissioner		
Office of Chief Counsel	Chelsea Durgan	Chelsea.Durgan@fda.hhs.gov		
Office of Food Policy and	Jason Cornell	jason.cornell@fda.hhs.gov		
Response				
Center for Food Safety and Applied Nutrition				
Office of International	Amy Fitzpatrick	Amy.Fitzpatrick@fda.hhs.gov		
Engagement		FDA-CFSAN-International-		
		Engagement@fda.hhs.gov		
Office of Food Safety	Tim Jackson	Timothy.Jackson@fda.hhs.gov		
Senior Science Advisor				
OFS/Division of Seafood	Jennifer Cripe	Jennifer.Cripe@fda.hhs.gov		
Safety				
Office of Compliance	Kathy Darlington (RPRT)	Leonora.Darlington@fda.hhs.gov		
	Arma White (RPRT)	Arma.White@fda.hhs.gov		
	Rose Sexton (FAAB)	Rosemary.Sexton@fda.hhs.gov		
	Lisa Thursam	Lisa.Thursam@fda.hhs.gov		
	(FAAB)			
	Leslie Hintz (SME)	Leslie.Hintz@fda.hhs.gov		
		cfsanocrert1@fda.hhs.gov		

Office of Analytics and	Yan Luo	Yan.Luo@fda.hhs.gov		
Outreach/Biostatistics and	Tun Euc	Tun.Due (g.Tun.Ims.ge v		
Bioinformatics Staff				
Centers for Disease Control and Prevention				
Division of Foodborne,	Angelo Lodato	ekp1@cdc.gov		
Waterborne, &	Laura Gieraltowski	hvq4@cdc.gov		
Environmental Diseases	Colin Schwensohn	lax2@cdc.gov		
Outbreak Response and		CDC comms		
Prevention Branch				
(ORPB)				
CDC Comms				
State Partners				
FL	SC			
MO	TN			
OH	TX			
Office of Coordinated Outbreak Response and Evaluation				
Senior Leadership	Stic Harris	CORESeniorLeadershipTeam@fda.hhs.gov		
	Kari Irvin			
	Karen Blickenstaff			
	Susan Lance			
Signals	Tiffany Greenlee	Tiffany.Greenlee@fda.hhs.gov		
	Allison Wellman	Allison.Wellman@fda.hhs.gov		
Outbreak Evaluation	Alphonso Haupt	Alphonso.Haupt@fda.hhs.gov		
Communications	Lindsay Walerstein	Lindsay.Walerstein@fda.hhs.gov		
		CORECommunications@fda.hhs.gov		
CORE Response Team 1	Alvin Crosby (T/L)	COREResponseTeam1@fda.hhs.gov		
	Brooke Whitney			
	(Lead)			
	Monica McClure			
	(Ops)			
	Sharon Seelman			
	(Planning)			